<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2023-12-20T11:46:50.6Z

Version        : 1.13
Last update    : $LastChangedDate: 2023-08-02 14:53:35 +0100 (Wed, 02 Aug 2023) $
Modified by    : $LastChangedBy: dunnm $

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J Open</journal-id><journal-id journal-id-type="iso-abbrev">Eur Heart J Open</journal-id><journal-id journal-id-type="publisher-id">ehjopen</journal-id><journal-title-group><journal-title>European Heart Journal Open</journal-title></journal-title-group><issn pub-type="epub">2752-4191</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38035039</article-id><article-id pub-id-type="pmc">PMC10684293</article-id>
<article-id pub-id-type="doi">10.1093/ehjopen/oead115</article-id><article-id pub-id-type="publisher-id">oead115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject><subj-group subj-group-type="category-toc-heading"><subject>Epidemiology and Prevention</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00200</subject></subj-group></article-categories><title-group><article-title>Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0853-5141</contrib-id><name><surname>B&#x000e4;ck</surname><given-names>Magnus</given-names></name><aff>
<institution>CArdiovascularREsolution of INflammation to promote HEALTH (CARE-IN-HEALTH) Consortium</institution>
</aff><aff>
<institution>Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff><aff>
<institution>Department of Medicine Solna, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff><aff>
<institution>Nancy University Hospital, University of Lorraine and INSERM U1116</institution>, <addr-line>9 avenue de la Foret de Haye, BP 20199</addr-line>, 54505 Vandoeuvre les Nancy Cedex, <country country="FR">France</country></aff><xref rid="oead115-cor1" ref-type="corresp"/><!--Magnus.Back@ki.se--></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Latini</surname><given-names>Roberto</given-names></name><aff>
<institution>CArdiovascularREsolution of INflammation to promote HEALTH (CARE-IN-HEALTH) Consortium</institution>
</aff><aff>
<institution>Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri&#x02014;IRCCS</institution>, <addr-line>Via Mario Negri, 2</addr-line>, 20156 Milano, <country country="IT">Italy</country></aff><xref rid="oead115-cor1" ref-type="corresp"/><!--roberto.latini@marionegri.it--><xref rid="oead114-FM1" ref-type="author-notes"/><xref rid="oead114-FM2" ref-type="author-notes"/></contrib></contrib-group><author-notes><fn id="oead114-FM1"><p>The opinions expressed in this article are not necessarily those of the Editors of the <italic toggle="yes">European Heart Journal Open</italic> or of the European Society of Cardiology.</p></fn><fn id="oead114-FM2" fn-type="COI-statement"><p>
<bold>Conflict of interest:</bold> None declared.</p></fn><corresp id="oead115-cor1">Corresponding author. Tel: +46 8 12380000, Email: <email>Magnus.Back@ki.se</email> (M.B.); Email: <email>roberto.latini@marionegri.it</email> (R.L.)</corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-11-12"><day>12</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>11</month><year>2023</year></pub-date><volume>3</volume><issue>6</issue><elocation-id>oead115</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="oead115.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" id="RA1" xlink:href="10.1093/ehjopen/oead114"/><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>European Union</institution><institution-id institution-id-type="DOI">10.13039/501100000780</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>HORIZON Research and Innovation Actions</institution></institution-wrap>
</funding-source><award-id>101095413</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>European Union</institution><institution-id institution-id-type="DOI">10.13039/501100000780</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>European Health and Digital Executive Agency</institution><institution-id institution-id-type="DOI">10.13039/100020655</institution-id></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="2"/></counts></article-meta></front><body><p>
<bold>This editorial refers to &#x02018;Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn&#x02019;, by M. Miller <italic toggle="yes">et al</italic>. <ext-link xlink:href="https://doi.org/10.1093/ehjopen/oead114" ext-link-type="uri">https://doi.org/10.1093/ehjopen/oead114</ext-link>.</bold>
</p><p>Studies of cardiovascular (CV) preventive strategies with high-dose omega-3 polyunsaturated fatty acids (n-3 PUFA) in subjects with hypertriglyceridaemia have generated differential results, which may relate to PUFA formulations, dosing and relative content of the two n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).<sup><xref rid="oead115-B1" ref-type="bibr">1</xref></sup> The n-3 PUFA-induced triglyceride lowering has also been suggested to be independent of the either beneficial or neutral cardiovascular outcomes in hypertriglyceridaemic subjects.<sup><xref rid="oead115-B1" ref-type="bibr">1</xref>,<xref rid="oead115-B2" ref-type="bibr">2</xref></sup> Importantly, hypertriglyceridaemia is one of the criteria for metabolic syndrome (MetSyn) combined with increased waist circumference and blood pressure as well as high glucose and low HDL levels.</p><p>In this issue of <italic toggle="yes">European Heart Journal Open</italic>, a pre-specified MetSyn subgroup analysis, including 35% of the 8179 patients enrolled in REDUCE-IT,<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> showed an applicability of the beneficial effects of the EPA formulation icosapent etyl (IPE) on the primary composite endpoint in subjects with MetSyn without diabetes.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> Among the endpoint components, myocardial infarction, coronary revascularization, and unstable angina requiring hospitalization were significantly lower in IPE vs. placebo in line with results obtained in the total study population.<sup><xref rid="oead115-B2" ref-type="bibr">2</xref></sup> In contrast, the reduced risk for cardiovascular death and stroke in REDUCE-IT<sup><xref rid="oead115-B2" ref-type="bibr">2</xref></sup> were not significant in the REDUCE-IT MetSyn subgroup,<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> which may illustrate the increased MetSyn risk profile. Finally, IPE increased hospitalization for either atrial fibrillation or flutter events in the MetSyn subgroup and did not alter risk of new onset diabetes.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup></p><p>The authors conclude that these results support that IPE reduces the high CV risk MetSyn phenotype despite lacking robust effects on MetSyn components apart from triglyceride lowering.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> Interestingly, an analysis of the individual MetSyn components (except triglycerides) revealed that IPE significantly reduced primary endpoint risk independently of the fulfilment of the waist circumference and elevated fasting glucose MetSyn criteria at baseline.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> In contrast, the IPE-induced effects were less pronounced and non-significant in the absence of blood pressure and HDL criteria.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup></p><p>One of the challenges in the interpretation of variable results of cardiovascular outcomes in clinical trials of omega-3 PUFA in addition to differences in doses, formulations and the EPA/DHA content, is identifying factors distinguishing responders from non-responders to omega-3 PUFA treatment.<sup><xref rid="oead115-B1" ref-type="bibr">1</xref></sup> Differential effects of IPE depending on the MetSyn criteria<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> opens up for future studies of blood pressure and HDL as possible factors to take into consideration in a personalized dimension for n-3 PUFA indications in cardiovascular prevention. Other possible underlying factors to a personalized response to n-3 PUFA intake and supplementation include genetic variations in fatty acid metabolism. For example, polymorphisms within the fatty acid desaturases (FADS) 1 and 2 FADS loci alter desaturase activity, which influence PUFA levels following n-3 PUFA supplementation or dietary intake and associate with measures of cardiovascular risk.<sup><xref rid="oead115-B4" ref-type="bibr">4</xref></sup></p><p>Omega-3 PUFAs also serve as the substrate for bioactive lipid mediators. The release of EPA from IPE provides the precursors for biosynthesis of resolvin E1, which mediates an active resolution of inflammation.<sup><xref rid="oead115-B1" ref-type="bibr">1</xref></sup> The contribution of low-grade non-resolving chronic inflammation in atherosclerotic cardiovascular disease has been well established. MetSyn represents an increased inflammatory state and median plasma concentration of hsCRP were slightly elevated (1.9&#x02005;mg/L) in the REDUCE-IT MetSyn population.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> Previous reports on biomarkers in REDUCE-IT indicated minor changes in hsCRP levels by IPE treatment.<sup><xref rid="oead115-B5" ref-type="bibr">5</xref></sup> No prospective data were provided for the effects of treatment on hsCRP in subjects with MetSyn, and potential changes in the MetSyn components measures were also not reported in the REDUCE-IT MetSyn subgroup analysis.<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup></p><p>The results presented in this issue of <italic toggle="yes">European Heart Journal Open</italic> that IPE reduced cardiovascular events in subjects with MetSyn<sup><xref rid="oead115-B3" ref-type="bibr">3</xref></sup> extends the knowledge on omega-3 PUFA in cardiovascular prevention. The observations on IPE cardiovascular risk prevention according to MetSyn criteria add new clues to the genetic and inflammation paths that are currently followed in the quest for identifying responders and non-responders to omega-3 PUFA cardiovascular prevention.</p></body><back><sec sec-type="data-availability" id="oead115-s0"><title>Data availability</title><p>No new data were generated or analysed in the preparation of this editorial.</p></sec><sec id="oead115-s1"><title>Disclosure</title><p>Magnus B&#x000e4;cks&#x02019; institution has received speaker and consultant fees from Amarin, Amgen, Heel, Novartis, and KabiFresenius.</p></sec><sec id="oead115-s2"><title>Funding</title><p>CARE-IN-HEALTH is funded by the European Union within HORIZON EUROPE Health Framework Programme under grant agreement 101095413. Views and opinions expressed are however those of the authors and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency.</p></sec><ref-list id="ref1"><title>References</title><ref id="oead115-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>B&#x000e4;ck</surname> &#x000a0;<given-names>M</given-names></string-name>
</person-group>. <article-title>Icosapent ethyl in cardiovascular prevention: resolution of inflammation through the eicosapentaenoic acid&#x02014;resolvin E1&#x02014;ChemR23 axis</article-title>. <source>Pharmacol Ther</source> &#x000a0;<year>2023</year>;<volume>247</volume>:<fpage>108439</fpage>.<pub-id pub-id-type="pmid">37201735</pub-id>
</mixed-citation></ref><ref id="oead115-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhatt</surname> &#x000a0;<given-names>DL</given-names></string-name>, <string-name><surname>Steg</surname> &#x000a0;<given-names>PG</given-names></string-name>, <string-name><surname>Miller</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname> &#x000a0;<given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname> &#x000a0;<given-names>TA</given-names></string-name>, <string-name><surname>Ketchum</surname> &#x000a0;<given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname> &#x000a0;<given-names>RT</given-names> &#x000a0;<suffix>Jr</suffix></string-name>, <string-name><surname>Juliano</surname> &#x000a0;<given-names>RA</given-names></string-name>, <string-name><surname>Jiao</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Granowitz</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Tardif</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Ballantyne</surname> &#x000a0;<given-names>CM</given-names></string-name>; <collab>REDUCE-IT Investigators</collab></person-group>. <article-title>Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia</article-title>. <source>N Engl J Med</source> &#x000a0;<year>2019</year>;<volume>380</volume>:<fpage>11</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">30415628</pub-id>
</mixed-citation></ref><ref id="oead115-B3"><label>3</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<string-name>
<surname>Miller</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Bhatt</surname> &#x000a0;<given-names>DL</given-names></string-name>, <string-name><surname>Brinton</surname> &#x000a0;<given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname> &#x000a0;<given-names>TA</given-names></string-name>, <string-name><surname>Gabriel Steg</surname> &#x000a0;<given-names>Ph.</given-names></string-name>, <string-name><surname>Pineda</surname> &#x000a0;<given-names>AL</given-names></string-name>, <string-name><surname>Ketchum</surname> &#x000a0;<given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname> &#x000a0;<given-names>RT</given-names> &#x000a0;<suffix>Jr</suffix></string-name>, <string-name><surname>Tardif</surname> &#x000a0;<given-names>J-C</given-names></string-name>, <string-name><surname>Ballantyne</surname> &#x000a0;<given-names>CM</given-names></string-name></person-group>; <comment>on Behalf of the REDUCE-IT Investigators</comment>. <article-title>Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn</article-title>. <source>Eur Heart J Open</source> &#x000a0;<year>2023</year>;doi:<pub-id pub-id-type="doi">10.1093/ehjopen/oead114</pub-id>.</mixed-citation></ref><ref id="oead115-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>B&#x000e4;ck</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Xhaard</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Rouget</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Thuillier</surname> &#x000a0;<given-names>Q</given-names></string-name>, <string-name><surname>Plunde</surname> &#x000a0;<given-names>O</given-names></string-name>, <string-name><surname>Larsson</surname> &#x000a0;<given-names>SC</given-names></string-name>, <string-name><surname>Girerd</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Ferreira</surname> &#x000a0;<given-names>JP</given-names></string-name>, <string-name><surname>Boivin</surname> &#x000a0;<given-names>JM</given-names></string-name>, <string-name><surname>Bozec</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Merckle</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Zannad</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Hoge</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Guillaume</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Dandine-Roulland</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Floch</surname> &#x000a0;<given-names>EL</given-names></string-name>, <string-name><surname>Bacq-Daian</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Deleuze</surname> &#x000a0;<given-names>JF</given-names></string-name>, <string-name><surname>Van den Berghe</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Nazare</surname> &#x000a0;<given-names>JA</given-names></string-name>, <string-name><surname>Laville</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Branlant</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Behm-Ansmant</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Wagner</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Rossignol</surname> &#x000a0;<given-names>P</given-names></string-name></person-group>. <article-title>Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness</article-title>. <source>Eur Heart J Open</source> &#x000a0;<year>2022</year>;<volume>2</volume>:<fpage>oeac016</fpage>.<pub-id pub-id-type="pmid">35919123</pub-id>
</mixed-citation></ref><ref id="oead115-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ridker</surname> &#x000a0;<given-names>PM</given-names></string-name>, <string-name><surname>Rifai</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>MacFadyen</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Glynn</surname> &#x000a0;<given-names>RJ</given-names></string-name>, <string-name><surname>Jiao</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Steg</surname> &#x000a0;<given-names>PG</given-names></string-name>, <string-name><surname>Miller</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname> &#x000a0;<given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname> &#x000a0;<given-names>TA</given-names></string-name>, <string-name><surname>Tardif</surname> &#x000a0;<given-names>JC</given-names></string-name>, <string-name><surname>Ballantyne</surname> &#x000a0;<given-names>CM</given-names></string-name>, <string-name><surname>Mason</surname> &#x000a0;<given-names>RP</given-names></string-name>, <string-name><surname>Bhatt</surname> &#x000a0;<given-names>DL</given-names></string-name></person-group>. <article-title>Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT Biomarker Substudy</article-title>. <source>Circulation</source> &#x000a0;<year>2022</year>;<volume>146</volume>:<fpage>372</fpage>&#x02013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">35762321</pub-id>
</mixed-citation></ref></ref-list></back></article>
